Camber Launches Eletriptan Hydrobromide Tablets
  Camber Pharmaceuticals continues to strengthen its range of treatment options with the introduction of Eletriptan Hydrobromide Tablets [EL-e-TRIP-tan].
Eletriptan Hydrobromide Tablets are indicated for the acute treatment of migraine, with or without aura in adults.
Eletriptan Hydrobromide Tablets are available in:
| 
 Strength  | 
Size | 
| 20 mg | 
 6 (1 x 6) Unit-dose Tablets  | 
| 40 mg | 
 6 (1 x 6) Unit-dose Tablets  | 
To learn more about this product, visit: www.camberpharma.com/eletriptan-hydrobromide
Recent articles
- Camber Launches Eletriptan Hydrobromide Tablets
 - Camber Launches Abacavir and Lamivudine Tablets, USP
 - Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
 - Camber Adds 800 mg Darunavir Tablets to Product Family
 - Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
 - Camber Launches Indomethacin Suppositories
 





